Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
The definition of chemotherapy does NOT say that chemo has to cause collateral damage to kill cancer cells. MGUS and SMM are considered to be asymptomatic blood-disorders. These two diagnoses are not cancer. If you don’t want to “watch and wait,” pursue evidence-based, non-toxic therapies to reduce the risk of MGUS/SMM from growing into multiple myeloma.
MGUS at a glance- click the image below now-
My experience as a long-term myeloma survivor and MM Cancer Coach is that MGUS and SMM patients do not want to watch and wait for their blood disorder to become full-blown multiple myeloma. At the same time, newly diagnosed MGUS and SMMers don’t want to live through toxic chemotherapy with all of the side effects.
The answer is evidence-based, non-conventional therapies that research has shown will reduce your risk of progression to multiple myeloma.
To learn more about the evidence-based protocols you can follow to prevent your Pre-Myeloma from becoming Multiple Myeloma, please watch the short video below:
If you have a question, scroll down the page, post a question or a comment and I will reply to you ASAP.
“The words ‘side effect’ usually evoke a mixture of fear and anxiety in cancer patients receiving chemotherapy…
Polverini’s group first reported anti-angiogenic effects mediated by conventional cytotoxic anticancer drugs as long ago as 15 years, and since then most common anticancer chemotherapeutic agents, belonging to all major classes, have been shown to be capable of inhibiting angiogenesis . This prompted George Sledge and colleagues recently to suggest the notion of ‘redefining’ chemotherapeutic drugs as anti-angiogenics…
What would be the advantage of using chemotherapeutics as possible angiogenesis inhibitors?… Thus, the hypothetical beneficial anti-angiogenic side effect of chemotherapy would seem negligible, or minimal, at best…
This method of administrating chemotherapy was dubbed ‘anti-angiogenic chemotherapy’ by Browder et al.  or ‘metronomic’ dosing by Hanahan et al. ; the latter term implies regular, frequent administration of drug, which requires lower doses to be used…